FDA moves to exclude weight loss drugs from compounding chemicals list

US Proposes Restricting Weight-Loss Drug Copies

The US Food and Drug Administration on Thursday proposed excluding active ingredients in drugs used to treat obesity and diabetes from a bulk list available to outsourcing facilities. Doing so would further restrict such facilities from legally manufacturing copies of these drugs by “compounding.” “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical ne…

FDA proposes curbs on mass copycats of Novo, Lilly's weight-loss drugs

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list.

FDA wants to limit knockoff versions of weight loss drugs like Ozempic and Zepbound

The FDA proposed excluding Novo Nordisk ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing facilities.

What did FDA propose about compounding weight-loss drugs?

FDA proposal targets compounding using obesity and diabetes drug ingredients The U.S. Food and Drug Administration has proposed excluding the active ingredients in certain widely used weight loss and diabetes medicines from a list of substances that can be used in compounding. The move is aimed at…

FDA moves to exclude weight loss drugs from compounding chemicals list

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.

FDA wants to exclude weight loss drugs from a compounding list

FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.